These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 18391604

  • 1. Sorafenib for metastatic renal cancer: the Princess Margaret experience.
    Riechelmann RP, Chin S, Wang L, Tannock IF, Berthold DR, Moore MJ, Knox JJ.
    Am J Clin Oncol; 2008 Apr; 31(2):182-7. PubMed ID: 18391604
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
    Stadler WM, Figlin RA, McDermott DF, Dutcher JP, Knox JJ, Miller WH, Hainsworth JD, Henderson CA, George JR, Hajdenberg J, Kindwall-Keller TL, Ernstoff MS, Drabkin HA, Curti BD, Chu L, Ryan CW, Hotte SJ, Xia C, Cupit L, Bukowski RM, ARCCS Study Investigators.
    Cancer; 2010 Mar 01; 116(5):1272-80. PubMed ID: 20082451
    [Abstract] [Full Text] [Related]

  • 3. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
    Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S.
    Jpn J Clin Oncol; 2007 Oct 01; 37(10):755-62. PubMed ID: 17951335
    [Abstract] [Full Text] [Related]

  • 4. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
    Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ.
    J Clin Oncol; 2006 Jun 01; 24(16):2505-12. PubMed ID: 16636341
    [Abstract] [Full Text] [Related]

  • 5. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
    Wörns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, Teufel A, Schuchmann M, Kanzler S, Düber C, Otto G, Galle PR.
    J Clin Gastroenterol; 2009 Jun 01; 43(5):489-95. PubMed ID: 19247201
    [Abstract] [Full Text] [Related]

  • 6. Sorafenib for the treatment of advanced renal cell carcinoma.
    Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D, Sridhara R, Garvey P, Justice R, Pazdur R.
    Clin Cancer Res; 2006 Dec 15; 12(24):7271-8. PubMed ID: 17189398
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
    Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB.
    J Clin Oncol; 2006 Sep 10; 24(26):4293-300. PubMed ID: 16908937
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
    Autier J, Escudier B, Wechsler J, Spatz A, Robert C.
    Arch Dermatol; 2008 Jul 10; 144(7):886-92. PubMed ID: 18645140
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.
    Harzstark AL, Small EJ, Weinberg VK, Sun J, Ryan CJ, Lin AM, Fong L, Brocks DR, Rosenberg JE.
    Cancer; 2011 Sep 15; 117(18):4194-200. PubMed ID: 21387258
    [Abstract] [Full Text] [Related]

  • 17. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer.
    Bianchi G, Loibl S, Zamagni C, Salvagni S, Raab G, Siena S, Laferriere N, Peña C, Lathia C, Bergamini L, Gianni L.
    Anticancer Drugs; 2009 Aug 15; 20(7):616-24. PubMed ID: 19739318
    [Abstract] [Full Text] [Related]

  • 18. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
    Yang CH, Lin WC, Chuang CK, Chang YC, Pang ST, Lin YC, Kuo TT, Hsieh JJ, Chang JW.
    Br J Dermatol; 2008 Mar 15; 158(3):592-6. PubMed ID: 18070211
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Sorafenib: a promising new targeted therapy for renal cell carcinoma.
    Wood LS, Manchen B.
    Clin J Oncol Nurs; 2007 Oct 15; 11(5):649-56. PubMed ID: 17962173
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.